Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Martijn Vlaming"'
Autor:
Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
A higher density of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment, particularly cytotoxic CD8+ T cells, is associated with improved clinical outcome in various cancers. However, local inhibitory factors can suppress T cell activ
Externí odkaz:
https://doaj.org/article/1dd027660af844b49d8b8cf3bd413551
Autor:
Ewa Cendrowicz, Lisa Jacob, Shirley Greenwald, Ami Tamir, Iris Pecker, Rinat Tabakman, Lucy Ghantous, Liat Tamir, Roy Kahn, Jasmine Avichzer, Alexandra Aronin, Shira Amsili, Elina Zorde-Khvalevsky, Yosi Gozlan, Martijn Vlaming, Gerwin Huls, Tom van Meerten, Michal Elhalel Dranitzki, Adam Foley-Comer, Yaron Pereg, Amnon Peled, Ayelet Chajut, Edwin Bremer
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-16 (2022)
Abstract Background Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combina
Externí odkaz:
https://doaj.org/article/88f427a2882642b7b2f32986f378f0e2
Autor:
Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases. Further, we previously identified that the level of CD20-positive T cell
Externí odkaz:
https://doaj.org/article/5b0c52b51ccf44eb9aa17073f9d75dfd
Autor:
Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Vinicio Melo, Annechien Plat, Gerwin Huls, Hans W. Nijman, Marco de Bruyn, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Reactivation of tumor infiltrating T lymphocytes (TILs) with immune checkpoint inhibitors or co-stimulators has proven to be an effective anti-cancer strategy for a broad range of malignancies. However, epithelial ovarian cancer (EOC) remains largely
Externí odkaz:
https://doaj.org/article/465eb515f65948b7a151ebb599965783
Publikováno v:
Cancer Research. 83:5662-5662
Bispecifics targeting multiple antigens or epitopes have been showing great promise for treatment of cancer. However, managing unwanted immunogenicity has become a challenge in the development cycle of these promising therapeutics as there is a trend
Publikováno v:
Cancer Research. 83:5146-5146
Neutrophils have shown a lot of plasticity with important consequences on cancer disease progression and have been associated with multiple functions such as killing antibody-opsonized cancer cells, directly kill tumor cells through the release of re
Publikováno v:
Cancer Research. 83:5168-5168
The increasing interest in the tumor microenvironment leads to a focus on new bioassays to represent all the players of the cancer immune response. Some of these players like regulatory T cells play an important role by downregulating the anti-tumor
Publikováno v:
Cancers
Cancers, Vol 14, Iss 299, p 299 (2022)
Cancers, Vol 14, Iss 299, p 299 (2022)
Simple Summary Members of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF) provide crucial co-stimulatory signals to many if not all immune effector cells. With distinct and unique functional features on multiple types of immune effector cells
Publikováno v:
Cancer Research. 82:1389-1389
The need to better understand the tumor microenvironment (TME) dictates the characterization of the cell types involved, the roles they play and how they respond to treatment. To develop novel cancer immunotherapies, in vitro primary immune cell bioa
Publikováno v:
Cancer Research. 82:2120-2120
Targeted activation of tumor infiltrating lymphocytes in the tumor microenvironment (TME) with so-called immune checkpoint inhibitors (ICIs) has resulted in the development of revolutionizing therapeutic anti-tumor strategies. A deepening understandi